Company research
Atai Beckley N.V.
CIK 1840904Updated Oct 6, 2026
Filing activity
50 filings on record · 15-12G, POSASR, 8-K, 424B7, 10-Q, 425.
About the company
AtaiBeckley is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments. It was formed through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited in November 2025. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (buccal film DMT) for TRD and EMP-01 (oral R-MDMA) for social anxiety disorder, which are in Phase 2 clinical development. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create new possibilities in mental health by providing effective, commercially scalable and convenient interventional psychiatry therapies that can integrate seamlessly into healthcare systems.
Recent filings
15-12G filing
POSASR filing
Other Events
Items 8.01, 9.01
424B7 filing
10-Q filing
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01, 9.01
424B7 filing
Completion of Acquisition or Disposition of Assets · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 2.01, 3.02, 7.01, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 159,387,000Source | 293,478,000Source | 305,441,000Source | 414,166,000Source |
| Property, Plant and Equipment, NetUSD | 2,535,000Source | 981,000Source | 928,000Source | 149,000Source |
| GoodwillUSD | 331,000Source | — | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 3,246,000Source | — | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 17,505,000Source | 45,034,000Source | 190,613,000Source | 362,266,000Source |
| Assets, CurrentUSD | 80,125,000Source | 185,592,000Source | 287,145,000Source | 375,082,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,795,000Source | 5,830,000Source | 14,036,000Source | 11,903,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,334,000Source | 1,223,000Source | 200,000Source | — |
| Other Assets, NoncurrentUSD | 850,000Source | 2,720,000Source | 3,351,000Source | 7,341,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 42,833,000Source | 49,162,000Source | 39,675,000Source | 28,207,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 18,785,000Source | 18,573,000Source | 18,562,000Source | 18,002,000Source |
| Additional Paid in CapitalUSD | 816,185,000Source | 794,787,000Source | 774,092,000Source | 725,045,000Source |
| Retained Earnings (Accumulated Deficit)USD | -700,207,000Source | -550,938,000Source | -510,188,000Source | -357,803,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -18,466,000Source | -19,460,000Source | -21,702,000Source | -8,336,000Source |
| Stockholders' Equity Attributable to ParentUSD | 116,297,000Source | 242,962,000Source | 260,740,000Source | 376,908,000Source |
| Liabilities and EquityUSD | 159,387,000Source | 293,478,000Source | 305,441,000Source | 414,166,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 24,951,000Source | 20,120,000Source | 19,897,000Source | 20,935,000Source |
| Operating Lease, Liability, CurrentUSD | 477,000Source | 275,000Source | 100,000Source | — |
| Accounts Payable, CurrentUSD | 2,616,000Source | 4,589,000Source | 2,399,000Source | 6,004,000Source |
| Operating Lease, Liability, NoncurrentUSD | 732,000Source | 990,000Source | 100,000Source | — |
| Other Liabilities, NoncurrentUSD | 2,695,000Source | 7,918,000Source | 3,708,000Source | 4,097,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 257,000Source | 1,354,000Source | 5,026,000Source | 9,051,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 9,847,000Source | 15,256,000Source | 17,306,000Source | 14,829,000Source |
| Long-term DebtUSD | 14,133,000Source | 15,047,000Source | 14,702,000Source | — |
| Long-term Debt, Current MaturitiesUSD | 6,374,000Source | 0Source | 0Source | — |
| Redeemable Noncontrolling Interest, Equity, Carrying AmountUSD | — | — | 0Source | 0Source |
| Restricted Cash and Investments, CurrentUSD | 10,000,000Source | — | — | — |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -150,049,000Source | -43,895,000Source | -157,417,000Source | -174,244,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 473,000Source | 319,000Source | 168,000Source | 47,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 25,490,000Source | 32,982,000Source | 42,375,000Source | 63,362,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -1,872,000Source | 2,138,000Source | -3,034,000Source | 2,300,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | 0Source | 5,074,000Source | -5,106,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -82,437,000Source | -84,118,000Source | -104,467,000Source | -63,246,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 59,172,000Source | -53,295,000Source | -86,848,000Source | -81,276,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | — | 0Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 6,000Source | 259,000Source | 773,000Source | 173,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | — | — | — | 500,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 5,374,000Source | -8,355,000Source | 20,785,000Source | 409,862,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -17,529,000Source | -145,578,000Source | -171,653,000Source | 265,020,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 27,505,000Source | 45,034,000Source | 190,613,000Source | 362,266,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 2,159,000Source | 1,923,000Source | 508,000Source | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 200,000Source | — | — | — |
| DepreciationUSD | 200,000Source | — | — | — |
| Equity Method Investment, Realized Gain (Loss) on DisposalUSD | — | — | 0Source | 16,923,000Source |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | 3,800,000Source | 5,500,000Source | 0Source | -12,346,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -1,263,000Source | -894,000Source | 6,902,000Source | 8,481,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | -1,078,000Source | -799,000Source | 4,950,000Source | 11,346,000Source |
| General and Administrative ExpenseUSD | 47,544,000Source | 63,582,000Source | 70,350,000Source | 92,745,000Source |
| GoodwillUSD | 331,000Source | — | — | — |
| Goodwill, Impairment LossUSD | 0Source | — | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | 919,000Source | — | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | -2,000,000Source | -3,593,000Source | -16,006,000Source | -58,555,000Source |
| Income Tax Expense (Benefit)USD | -356,000Source | 1,016,000Source | 6,229,000Source | -3,989,000Source |
| InterestExpenseNonoperatingUSD | 3,124,000Source | — | — | — |
| Investment Income, InterestUSD | 778,000Source | 1,847,000Source | 548,000Source | 205,000Source |
| Net Income (Loss) Attributable to ParentUSD | -149,269,000Source | -40,224,000Source | -152,385,000Source | -167,808,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -780,000Source | -3,671,000Source | -5,032,000Source | -6,436,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -149,269,000Source | -40,224,000Source | — | — |
| Nonoperating Income (Expense)USD | -45,714,000Source | 86,185,000Source | 9,605,000Source | -796,000Source |
| Operating ExpensesUSD | 102,999,000Source | 125,785,000Source | 145,020,000Source | 156,181,000Source |
| Other Nonoperating Income (Expense)USD | -484,000Source | -189,000Source | -1,412,000Source | -293,000Source |
| Payments of Financing CostsUSD | 161,000Source | 100,000Source | 1,745,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | 0Source | 409,884,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 65,560,000Source | 138,983,000Source | 226,834,000Source | — |
| Proceeds from Noncontrolling InterestsUSD | — | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | 535,000Source | 205,000Source | 2,294,000Source | 935,000Source |
| Restricted Cash and Investments, CurrentUSD | 10,000,000Source | — | — | — |
| Restructuring CostsUSD | 2,029,000Source | 3,200,000Source | — | — |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Total RevenueUSD | 308,000Source | 314,000Source | 233,000Source | 20,376,000Source |
| Operating Income (Loss)USD | -102,691,000Source | -125,471,000Source | -144,787,000Source | -135,805,000Source |
| Other Nonoperating Income (Expense)USD | -484,000Source | -189,000Source | -1,412,000Source | -293,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -148,405,000Source | -39,286,000Source | -135,182,000Source | -136,601,000Source |
| Income Tax Expense (Benefit)USD | -356,000Source | 1,016,000Source | 6,229,000Source | -3,989,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -780,000Source | -3,671,000Source | -5,032,000Source | -6,436,000Source |
| Net Income (Loss) Attributable to ParentUSD | -149,269,000Source | -40,224,000Source | -152,385,000Source | -167,808,000Source |
| Earnings Per Share, BasicUSD per share | -0.93Source | -0.25Source | -0.98Source | — |
| Earnings Per Share, DilutedUSD per share | -0.93Source | -0.25Source | -0.98Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 160,159,983Source | 158,833,785Source | 155,719,585Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 160,159,983Source | 158,833,785Source | 155,719,585Source | — |
| Interest Expense (non-operating)USD | 3,124,000Source | — | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 200,000Source | — | — | — |
| Current Income Tax Expense (Benefit)USD | 356,000Source | 1,016,000Source | 1,155,000Source | 1,117,000Source |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | 3,800,000Source | 5,500,000Source | 0Source | -12,346,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -1,263,000Source | -894,000Source | 6,902,000Source | 8,481,000Source |
| General and Administrative ExpenseUSD | 47,544,000Source | 63,582,000Source | 70,350,000Source | 92,745,000Source |
| Goodwill, Impairment LossUSD | 0Source | — | — | — |
| Income (Loss) Attributable to Parent, before TaxUSD | -148,405,000Source | -39,286,000Source | -135,182,000Source | -136,601,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -95,551,000Source | 19,916,000Source | -55,845,000Source | -89,061,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | -2,000,000Source | -3,593,000Source | -16,006,000Source | -58,555,000Source |
| Interest ExpenseUSD | — | 2,656,000Source | — | — |
| Investment Income, InterestUSD | 778,000Source | 1,847,000Source | 548,000Source | 205,000Source |
| Labor and Related ExpenseUSD | 500,000Source | 500,000Source | 500,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -149,269,000Source | -40,224,000Source | — | — |
| Nonoperating Income (Expense)USD | -45,714,000Source | 86,185,000Source | 9,605,000Source | -796,000Source |
| Operating ExpensesUSD | 102,999,000Source | 125,785,000Source | 145,020,000Source | 156,181,000Source |
| Research and Development ExpenseUSD | 400,000Source | 2,000,000Source | — | — |
| Restructuring CostsUSD | 2,029,000Source | 3,200,000Source | — | — |
Filing attachments
ef20058743_ex99-1.htm · 8-K · 2025-11-12
EX-99.1 2 ef20058743_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights AtaiBeckley solidifies position as a global leader in transformative mental health therapies with a short psychedelic duration BPL-003 (mebufotenin benzoate nasal spray) granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for treatment-resistant depression (TRD) Reported positive topline data from the P…
Read attachment ↗ef20058318_ex99-1.htm · 8-K · 2025-11-05
EX-99.1 2 ef20058318_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies atai Life Sciences’ shareholders voted to approve the strategic combination with Beckley Psytech Limited and the corporate redomiciliation at the Extraordinary General Meeting of Shareholders on November 4, 2025, with approximately 98% of the vot…
Read attachment ↗ef20057467_ex99-1.htm · 8-K · 2025-10-21
EX-99.1 2 ef20057467_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003 NEW YORK and AMSTERDAM, October 20, 2025 - atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutic…
Read attachment ↗ef20057374_ex99-1.htm · 8-K · 2025-10-20
EX-99.1 4 ef20057374_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 atai Life Sciences Announces Pricing of Public Offering of Common Shares NEW YORK and AMSTERDAM, October 16, 2025 - atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 23,725,000 common shares, at a price of $5.48 per share. atai has granted the underwr…
Read attachment ↗ny20057248x2_ex99-1.htm · 8-K · 2025-10-16
EX-99.1 2 ny20057248x2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression Breakthrough Therapy designation recognizes the potential of BPL-003 to deliver substantial improvement over existing therapies for patients with treatment-resistant depression FDA designation follows previously announced Phase 2b topline data which showed…
Read attachment ↗ef20056757_ex99-1.htm · 8-K · 2025-10-10
EX-99.1 2 ef20056757_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BECKLEY PSYTECH LIMITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) FOR THE SIX MONTHS ENDED June 30, 2025 Beckley Psytech Limited Interim Condensed Consolidated Statement of Comprehensive Loss For the six months ended June 30, 2025 and 2024 (Unaudited) Notes 2025 2024 ─────────────────────────────────────────────────────────…
Read attachment ↗